Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance Therapeutics (RVNC) reported a substantial revenue increase for Q2 2021, reaching $18.8 million, a surge from $0.3 million in Q2 2020. Total revenue for the first half of 2021 was $32.1 million compared to $0.4 million last year. The growth is attributed to the RHA® Collection of dermal fillers and fintech platform sales. However, net losses widened to $72.2 million for Q2 2021, up from $60.6 million in Q2 2020. The company anticipates FDA approval for DaxibotulinumtoxinA in 2021, which could significantly bolster its aesthetics franchise.
Revance Therapeutics (Nasdaq: RVNC) will announce its second quarter 2021 financial results on August 5, 2021, after market close. A conference call and live webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the outcomes and business updates. Individuals can access the call by dialing specified numbers or through the webcast on Revance's investor relations webpage. Revance focuses on innovative aesthetic and therapeutic solutions, including the DaxibotulinumtoxinA for Injection, which is nearing U.S. regulatory approval after a successful Phase 3 program.
Revance Therapeutics (Nasdaq: RVNC) announced that CEO Mark Foley will speak at two upcoming conferences. He will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 1:20 p.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 p.m. PT. Live audio webcasts will be accessible via the Investor Relations section of Revance's website, and a replay will be available for 30 days post-conference. Revance specializes in aesthetic and therapeutic offerings, including its innovative neuromodulator, DaxibotulinumtoxinA for Injection.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the FDA will initiate a pre-approval inspection of its manufacturing facility for DaxibotulinumtoxinA for Injection by the end of June 2021. This follows a deferral from the FDA in November 2020 due to COVID-19 travel restrictions affecting inspection completion. Revance's DaxibotulinumtoxinA is advanced for treating glabellar lines and is currently in a Phase 3 program. Revance is also developing a biosimilar to BOTOX® in partnership with Viatris.
Revance Therapeutics, Inc. (Nasdaq: RVNC) reported a first quarter 2021 revenue of $13.3 million, a significant increase from $0.1 million in Q1 2020, driven primarily by the RHA® Collection of dermal fillers. However, the company faced a net loss of $71.6 million. SG&A expenses rose to $49.0 million, while R&D expenses decreased to $27.3 million. Cash equivalents stood at $386.8 million, and the company raised $21.7 million from its ATM program. The FDA's review of DaxibotulinumtoxinA for Injection remains pending due to inspection scheduling delays.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will release its first quarter 2021 financial results on May 10, 2021, after market close. A conference call and live webcast discussing these results will take place at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Revance is known for its neuromodulator product, DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials and is awaiting U.S. regulatory approval. The company also holds exclusive U.S. distribution rights for RHA® Collection dermal fillers and is developing a biosimilar to BOTOX® in partnership with Viatris.
Revance Therapeutics (Nasdaq: RVNC) announced a presentation at The American Society for Aesthetic Plastic Surgery Aesthetic Meeting 2021, highlighting data from the Phase 3 SAKURA clinical program. This analysis demonstrated the efficacy, safety, and duration of DaxibotulinumtoxinA for Injection in treating glabellar lines across various female age groups. With over 3,000 subjects, the data confirmed a median time to loss of none or mild symptoms lasting at least 24 weeks. Revance is seeking FDA approval for this treatment, aiming to transform patient experiences in the aesthetic and therapeutic markets.
Revance Therapeutics (Nasdaq: RVNC) has announced the initiation of Phase 3 trials for DaxibotulinumtoxinA in China, aimed at treating glabellar lines and cervical dystonia. The first patients were dosed in April 2023. The Chinese market for neuromodulators is rapidly growing, projected to expand from $318 million in 2021 to $762 million by 2027. Revance has a licensing agreement with Fosun Pharma, which includes potential milestone payments of $230 million and royalties based on future sales.
Revance Therapeutics has announced it will present four ePoster abstracts at the AAD VMX meeting from April 23-25, 2021. These presentations include new data from the SAKURA Phase 3 program for DaxibotulinumtoxinA for Injection, highlighting its effectiveness in eliminating glabellar lines. The abstracts also feature subgroup analysis of efficacy among adult females and the impact of hyaluronic acid filler manufacturing on HA chain degradation. Attendees can access sessions on-demand until July 12, 2021, via the AAD website.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the 20th Annual Needham Virtual Healthcare Conference from April 12-15. CEO Mark Foley is scheduled for a fireside chat on April 13 at 7:15 a.m. PT / 10:15 a.m. ET. Interested parties can access the live audio webcast via the Investor Relations section on www.revance.com. The conference will feature the company's innovative products, including DaxibotulinumtoxinA for Injection, a next-generation neuromodulator targeting various aesthetic and therapeutic applications.
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
